Rozenfeld-Granot G, Toren A, Amariglio N, Brok-Simoni F, Rechavi G
Pediatric Hemato-Oncology Department, Chaim Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Hashomer, Israel.
Exp Hematol. 2001 Feb;29(2):228-33. doi: 10.1016/s0301-472x(00)00623-8.
The existence of properly functioning apoptotic pathways is of utmost importance in the maintenance of a normal cell count. Several groups have searched for mutations in the FAS receptor, a well-characterized apoptotic protein carrying a death domain, and reported the existence of rare mutations in multiple myeloma, T-acute lymphoblastic leukemia (T-ALL), and adult T-cell leukemia. Our aim was to expand these searches by looking for mutations in the death domains of FAS, FADD, TNFR, TRADD, and RIP, in the promoter region of FAS, and in the protease domain of caspase 10, in a larger variety of hematological malignancies, some of which express an apoptosis-resistant phenotype.
We extracted RNA and DNA samples from 92 hematological malignancies: chronic lymphocytic leukemia (CLL; 31 cases), chronic myelogenous leukemia (CML; 28 cases), essential thrombocythemia (ET; 8 cases), acute lymphocytic leukemia (ALL; 6 cases), acute myeloblastic leukemia (AML; 6 cases), hairy-cell leukemia (HCL; 3 cases), Burkitt's lymphoma (3 cases), polycythemia vera (PV; 3 cases), myelofibrosis (2 cases), and chronic myelomonocytic leukemia (CMML; 2 cases) and performed PCR-SSCP and sequence analysis on these samples.
Five polymorphic patterns were found: three in the death domain of the FAS gene in CML patients, one in the promoter of this gene in a CLL patient, and the fifth in the death domain of the TRADD gene in a CML patient. No mutations, altering amino acids, were found in these genes in any of the aforementioned malignancies.
These observations imply that mutations in the death domains of FAS, FADD, TNFR, TRADD, and RIP and in the protease domain of caspase 10 are not a major cause for failure of apoptosis in hematological malignancies, mainly CML and CLL. Regulatory and epigenetic abnormalities in these apoptotic cascade members and aberrations in other components of all death machinery should be looked for.
正常运作的凋亡途径的存在对于维持正常细胞计数至关重要。多个研究小组在FAS受体(一种具有死亡结构域的特征明确的凋亡蛋白)中寻找突变,并报告在多发性骨髓瘤、T急性淋巴细胞白血病(T-ALL)和成人T细胞白血病中存在罕见突变。我们的目的是通过在更多种类的血液系统恶性肿瘤中寻找FAS、FADD、TNFR、TRADD和RIP的死亡结构域、FAS启动子区域以及半胱天冬酶10蛋白酶结构域中的突变来扩大这些研究,其中一些肿瘤表现出抗凋亡表型。
我们从92例血液系统恶性肿瘤中提取RNA和DNA样本,这些肿瘤包括慢性淋巴细胞白血病(CLL;31例)、慢性粒细胞白血病(CML;28例)、原发性血小板增多症(ET;8例)、急性淋巴细胞白血病(ALL;6例)、急性髓细胞白血病(AML;6例)、毛细胞白血病(HCL;3例)、伯基特淋巴瘤(3例)、真性红细胞增多症(PV;3例)、骨髓纤维化(2例)和慢性粒单核细胞白血病(CMML;2例),并对这些样本进行PCR-SSCP和序列分析。
发现了五种多态性模式:三种在CML患者的FAS基因死亡结构域中,一种在CLL患者的该基因启动子中,第五种在CML患者的TRADD基因死亡结构域中。在上述任何恶性肿瘤的这些基因中均未发现改变氨基酸的突变。
这些观察结果表明,FAS、FADD、TNFR、TRADD和RIP的死亡结构域以及半胱天冬酶10蛋白酶结构域中的突变不是血液系统恶性肿瘤(主要是CML和CLL)凋亡失败的主要原因。应该寻找这些凋亡级联成员中的调节和表观遗传异常以及所有死亡机制其他成分中的畸变。